Advanced search
Publication Cover
Acta Oncologica Volume 50, 2011 - Issue 4
Journal homepage
1,650
Views
52
CrossRef citations to date
0
Altmetric
Research Article

Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

Petri Bono Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Laboratory of Molecular Oncology, Molecular Cancer Biology Research Program, Biomedicum Helsinki, University of Helsinki, FinlandCorrespondence[email protected]
,
Juhana Rautiola Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
,
Tapio Utriainen Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
&
Heikki Joensuu Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Laboratory of Molecular Oncology, Molecular Cancer Biology Research Program, Biomedicum Helsinki, University of Helsinki, Finland
Pages 569-573 | Received 27 Jun 2010, Accepted 23 Nov 2010, Published online: 05 Jan 2011

Citations (52)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Yan Song, Tao Qu, Honggang Zhang, Yongkun Sun, Chengxu Cui, Yihebali Chi, Wen Zhang, Xingyuan Wang & Lin Yang. (2021) The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer. Cancer Management and Research 13, pages 6199-6205.
Read now
Yun-Ting Zhu, Zan Teng, Yi-Fan Zhang, Wei Li, Li-Xia Guo, Yun-Peng Liu, Xiu-Juan Qu, Quan-Ren Wang, Si-Yuan Mao, Xiao-Yan Chen & Da-Fang Zhong. (2020) Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors. Drug Design, Development and Therapy 14, pages 1963-1970.
Read now
Liyu Jiang, Li Ping, Hao Yan, Xiaochun Yang, Qiaojun He, Zhifei Xu & Peihua Luo. (2020) Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. Expert Opinion on Drug Metabolism & Toxicology 16:9, pages 823-835.
Read now
Matteo Santoni, Alessandro Conti, Francesco Massari, Vincenzo Di Nunno, Luca Faloppi, Eva Galizia, Jarno Morbiducci, Francesco Piva, Sebastiano Buti, Roberto Iacovelli, Benedetta Ferretti, Alessia Cimadamore, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli & Rodolfo Montironi. (2019) Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. Expert Review of Cardiovascular Therapy 17:12, pages 917-927.
Read now
Frede Donskov, Daniel Y C Heng & Brian I Rini. (2017) On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?. Expert Review of Anticancer Therapy 17:2, pages 97-99.
Read now
Anne V. Soerensen, Poul F. Geertsen, Ib J. Christensen, Gregers G. Hermann, Niels V. Jensen, Kirsten Fode, Astrid Petersen, Rickard Sandin & Frede Donskov. (2016) A five-factor biomarker profile obtained week 4–12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. Acta Oncologica 55:3, pages 341-348.
Read now
Pavan Mankal & Eileen O'Reilly. (2013) Sunitinib malate for the treatment of pancreas malignancies – where does it fit?. Expert Opinion on Pharmacotherapy 14:6, pages 783-792.
Read now

Articles from other publishers (45)

Hui-Jeong Hwang & Taek-Gu Lee. (2023) Impact on clinical outcomes of renin-angiotensin system inhibitors against doxorubicin-related toxicity in patients with breast cancer and hypertension: A nationwide cohort study in South Korea. PLOS ONE 18:11, pages e0294649.
Crossref
Miki Takenaka Sato, Ayuki Ida, Yuki Kanda, Kaori Takano, Masayuki Ohbayashi, Noriko Kohyama, Jun Morita, Kohzo Fuji, Haruaki Sasaki, Yoshio Ogawa & Mari Kogo. (2022) Prognostic model for overall survival that includes the combination of platelet count and neutrophil–lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma. BMC Cancer 22:1.
Crossref
Elena Bolzacchini, Monica Giordano, Lorenza Bertù, Marco Bregni, Olga Nigro, Luca Galli, Andrea Antonuzzo, Salvatore Artale, Sabrina Barzaghi, Marco Danova, Martina Torchio, Graziella Pinotti & Francesco Dentali. (2021) Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib. Tumori Journal 108:5, pages 502-509.
Crossref
Bhagyashri Chaudhari, Harun Patel, Snehal Thakar, Iqrar Ahmad & Deepali Bansode. (2022) Optimizing the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach. In Silico Pharmacology 10:1.
Crossref
Annemarie Uhlig, Johannes Uhlig, Lutz Trojan, Michael Woike, Marianne Leitsmann & Arne Strauß. (2021) Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer. Future Oncology 17:1, pages 45-56.
Crossref
Elena Bolzacchini, Graziella Pinotti, Lorenza Bertù, Claudio Verusio, Luca Galli, Nicola Mumoli, Cecilia Barbara, Marco Danova, Marco Bregni, Salvatore Artale, Chiara Rossini, Olga Nigro, Andrea Antonuzzo, Lisa Derosa, Martina Torchio, Sabrina Barzaghi, Isabella Ricci, Matteo Suter, Alice Ballerio, Ilaria Vallini & Francesco Dentali. (2020) On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study. Clinical Genitourinary Cancer 18:2, pages e145-e156.
Crossref
Yu Liu, Liang Zhou, Yuntian Chen, Banghua Liao, Donghui Ye, Kunjie Wang & Hong Li. (2019) Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. BMC Urology 19:1.
Crossref
Tetsuhide Ito, Masayuki Tori, Satoshi Hashigaki, Nobuyuki Kimura, Kazuo Sato, Emiko Ohki, Akira Sawaki & Takuji Okusaka. (2019) Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study. Japanese Journal of Clinical Oncology 49:4, pages 354-360.
Crossref
Jakub Kucharz, Monika Budnik, Paulina Dumnicka, Maciej Pastuszczak, Beata Kuśnierz-Cabala, Tomasz Demkow, Katarzyna Popko & Pawel Wiechno. 2019. Advances in Medicine and Medical Research. Advances in Medicine and Medical Research 35 40 .
Cody N. Justice, Mohamed H. Derbala, Tesla M. Baich, Amber N. Kempton, Aaron S. Guo, Thai H. Ho & Sakima A. Smith. (2018) The Impact of Pazopanib on the Cardiovascular System. Journal of Cardiovascular Pharmacology and Therapeutics 23:5, pages 387-398.
Crossref
Arduino A. Mangoni, Ganessan Kichenadasse, Andrew Rowland & Michael J. Sorich. (2018) Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study. Therapeutic Advances in Medical Oncology 10, pages 175883401875509.
Crossref
Ian D. Davis, Wanling Xie, Carmel Pezaro, Frede Donskov, J. Connor Wells, Neeraj Agarwal, Sandy Srinivas, Takeshi Yuasa, Benoit Beuselinck, Lori A. Wood, D. Scott Ernst, Ravindran Kanesvaran, Jennifer J. Knox, Allan Pantuck, Sadia Saleem, Ajjai Alva, Brian I. Rini, Jae-Lyun Lee, Toni K. Choueiri & Daniel Y.C. Heng. (2017) Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. European Urology 71:6, pages 970-978.
Crossref
Patrick Penttilä, Juhana Rautiola, Tuija Poussa, Katriina Peltola & Petri Bono. (2017) Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 15:3, pages 384-390.e3.
Crossref
Marjut Niinivirta, Gunilla Enblad, Per-Henrik Edqvist, Fredrik Pontén, Anca Dragomir & Gustav J. Ullenhag. (2017) Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib. Journal of Cancer Research and Clinical Oncology 143:6, pages 961-970.
Crossref
Fausto Petrelli, Giuseppina P. Dognini, Maurizio Destro & Sandro Barni. (2017) Hypertension and Survival in Renal Cell Carcinoma Treated with anti-VEGFR Agents: A Systematic Review and Meta-Analysis. Journal of Onco-Nephrology 1:2, pages 120-126.
Crossref
Gloria Ravegnini, Margherita Nannini, Corrado Zenesini, Vittorio Simeon, Giulia Sammarini, Milena Urbini, Lidia Gatto, Maristella Saponara, Guido Biasco, Maria A. Pantaleo, Nicola Venturoli, Patrizia Hrelia & Sabrina Angelini. (2016) An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis 20:1, pages 139-148.
Crossref
Aleksandra Semeniuk-Wojtaś, Arkadiusz Lubas, Rafał Stec, Cezary Szczylik & Stanisław Niemczyk. (2016) Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients. International Journal of Molecular Sciences 17:12, pages 2073.
Crossref
Petri Bono, Stephane Oudard, Istvan Bodrogi, Thomas E. Hutson, Bernard Escudier, Jean-Pascal Machiels, John A. Thompson, Robert A. Figlin, Alain Ravaud, Mert Basaran, Camillo Porta, Sergio Bracarda, Thomas Brechenmacher, Chinjune Lin, Maurizio Voi, Viktor Grunwald & Robert J. Motzer. (2016) Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clinical Genitourinary Cancer 14:5, pages 406-414.
Crossref
Jakub Kucharz, Agnieszka Giza, Paulina Dumnicka, Marek Kuzniewski, Beata Kusnierz-Cabala, Pawel Bryniarski, Roma Herman, Aneta Lidia Zygulska & Krzysztof Krzemieniecki. (2016) Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma. Medical Oncology 33:10.
Crossref
Krisztián Nagyiványi, Barna Budai, Krisztina Bíró, Fruzsina Gyergyay, László Noszek, Zsófia Küronya, Hajnalka Németh, Péter Nagy & Lajos Géczi. (2016) Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer 14:4, pages 314-322.
Crossref
Jacqueline S.L. Kloth, Paul Hamberg, Pauline A.J. Mendelaar, Roderick R. Dulfer, Bronno van der Holt, Karel Eechoute, Erik A.C. Wiemer, Wim H.J. Kruit, Stefan Sleijfer & Ron H.J. Mathijssen. (2016) Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment. European Journal of Cancer 56, pages 101-106.
Crossref
Juhana Rautiola, Frede Donskov, Katriina Peltola, Heikki Joensuu & Petri Bono. (2016) Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU International 117:1, pages 110-117.
Crossref
J.D. Rebibo, C. Pfister, A. Giwerc, G. Defortescu, S. Gouerant, F. Di Fiore & F.-X. Nouhaud. (2016) Étude des facteurs pronostiques pour le carcinome rénal métastatique traité par une deuxième ligne de thérapies ciblées. Progrès en Urologie 26:1, pages 16-23.
Crossref
Dave Lengel, Eva Lamm Bergström, Herb Barthlow, Karen Oldman, Helen Musgrove, Alex Harmer, Jean-Pierre Valentin, Paul Duffy, Martin Braddock & Jon Curwen. (2015) Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents. Pharmacology Research & Perspectives 3:5, pages e00176.
Crossref
Jakub Kucharz, Paulina Dumnicka, Marek Kuzniewski, Beata Kusnierz-Cabala, Roman Maria Herman & Krzysztof Krzemieniecki. (2015) Co-occurring Adverse Events Enable Early Prediction of Progression-free Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib: A Hypothesis-generating Study. Tumori Journal 101:5, pages 555-559.
Crossref
Beatrica Kurbel, Ante Zvonimir Golem & Sven Kurbel. (2015) Are predictions of cancer response to targeted drugs, based on effects in unrelated tissues, the ‘Black Swan’ events?. Future Oncology 11:16, pages 2307-2314.
Crossref
H. Izzedine, L. Derosa, G. Le Teuff, L. Albiges & B. Escudier. (2015) Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Annals of Oncology 26:6, pages 1128-1133.
Crossref
C. Rodríguez‐Antona & M. Taron. (2015) Pharmacogenomic biomarkers for personalized cancer treatment. Journal of Internal Medicine 277:2, pages 201-217.
Crossref
Noriyuki Akutsu, Shigeru Sasaki, Hideyasu Takagi, Masayo Motoya, Masahiro Shitani, Mai Igarashi, Daisuke Hirayama, Hideki Wakasugi, Hiroyuki Yamamoto, Hiroyuki Kaneto, Kazuhiko Yonezawa, Atsushi Yawata, Takeya Adachi, Yasuo Hamamoto & Yasuhisa Shinomura. (2014) Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. International Journal of Clinical Oncology 20:1, pages 105-110.
Crossref
Hong-kai Wang, Hai-liang Zhang, Yao Zhu, Xu-dong Yao, Shi-lin Zhang, Bo Dai, Yi-jun Shen, Yi-ping Zhu, Guo-hai Shi, Xiao-jian Qin, Chun-guang Ma, Guo-wen Lin, Wen-jun Xiao & Ding-wei Ye. (2014) A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma. Future Oncology 10:12, pages 1941-1951.
Crossref
F.-X. Nouhaud, J.-D. Rebibo, F. Blanchard, J.-C. Sabourin, F. Di Fiore & C. Pfister. (2014) Valeur pronostique de la toxicité induite par les thérapies ciblées dans le carcinome rénal métastatique. Progrès en Urologie 24:9, pages 563-571.
Crossref
Thomas Grellety, Camille Brugères-Chakiba, Axel Chaminade, Guilhem Roubaud, Alain Ravaud & Marine Gross-Goupil. (2014) Révision de l’index thérapeutique des thérapies ciblées dans le cancer du rein : le mieux peut-il être l’ennemi du bien ? La toxicité peut-elle prédire l’efficacité ?. Bulletin du Cancer 101:6, pages 608-618.
Crossref
Caroline Hilmi & Gilles Pagès. 2014. Anti-Angiogenesis Drug Discovery and Development. Anti-Angiogenesis Drug Discovery and Development 112 131 .
A. Ravaud & M. Schmidinger. (2013) Clinical biomarkers of response in advanced renal cell carcinoma. Annals of Oncology 24:12, pages 2935-2942.
Crossref
Juana Dornbusch, Aristeidis Zacharis, Matthias Meinhardt, Kati Erdmann, Ingmar Wolff, Michael Froehner, Manfred P. Wirth, Stefan Zastrow & Susanne Fuessel. (2013) Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma. PLoS ONE 8:9, pages e76386.
Crossref
Denis Soulières. (2013) Side-effects associated with targeted therapies in renal cell carcinoma. Current Opinion in Supportive & Palliative Care 7:3, pages 254-257.
Crossref
Ahmed Alasker, Malek Meskawi, Maxine Sun, Salima Ismail, Nawar Hanna, Jens Hansen, Zhe Tian, Marco Bianchi, Paul Perrotte & Pierre I. Karakiewicz. (2013) A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer Treatment Reviews 39:4, pages 388-401.
Crossref
Renata Ferrarotto & Paulo M. Hoff. (2013) Antiangiogenic Drugs for Colorectal Cancer: Exploring New Possibilities. Clinical Colorectal Cancer 12:1, pages 1-7.
Crossref
Massimo Gion & Aline S.C. Fabricio. (2018) Inflammation Markers: New Actors in the Cancer Biomarker Tale. The International Journal of Biological Markers 28:1, pages 1-2.
Crossref
Piotr Rutkowski, Elżbieta Bylina, Anna Klimczak, Tomasz Świtaj, Sławomir Falkowski, Jacek Kroc, Iwona Ługowska, Magdalena Brzeskwiniewicz, Wojciech Melerowicz, Czesław Osuch, Ewa Mierzejewska, Kacper Wasielewski, Agnieszka Woźniak, Urszula Grzesiakowska, Zbigniew I Nowecki, Janusz A Siedlecki & Janusz Limon. (2012) The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC Cancer 12:1.
Crossref
Cristina Rodríguez-Antona & Jesús García-Donas. (2012) Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma. Pharmacogenomics 13:14, pages 1621-1633.
Crossref
K Eechoute, A A M van der Veldt, S Oosting, M H W Kappers, J A M Wessels, H Gelderblom, H-J Guchelaar, A K L Reyners, C M L van Herpen, J B Haanen, R H J Mathijssen & E Boven. (2012) Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension. Clinical Pharmacology & Therapeutics.
Crossref
Aiping ZHOU. (2012) Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience. Asia-Pacific Journal of Clinical Oncology 8:2, pages 132-144.
Crossref
I. Yildiz, F. Sen, M. Basaran, M. Ekenel, F. Agaoglu, E. Darendeliler, H. M. Tunc, F. Ozcan & S. Bavbek. (2011) Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey. Japanese Journal of Clinical Oncology 41:12, pages 1380-1387.
Crossref
K. Webber, A. Cooper, H. Kleiven, D. Yip & D. Goldstein. (2011) Management of metastatic renal cell carcinoma in the era of targeted therapies. Internal Medicine Journal 41:8, pages 594-605.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.